Drug Profile

RVX sCPD9 vaccine

Alternative Names: RVX-sCodon Pair Deoptimization9 vaccine; RVX-sCPD9

Latest Information Update: 24 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ROCKETVAX
Class Attenuated vaccines; COVID-19 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical COVID 2019 infections

Most Recent Events

13 Jun 2024 Rocketvax and US National Institutes of Health (NIH) agree to co-develop RVX-sCPD9 for COVID-2019 infections
13 Jun 2024 Preclinical trials in COVID-2019 infections in Switzerland (Intranasal) prior to June 2024 (Rocketvax Pipeline, July 2024)
13 Jun 2024 Rocketvax plans a phase I trial for COVID-2019 infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com